News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
700,053 Results
Type
Article (39741)
Company Profile (248)
Press Release (660064)
Multimedia
Podcasts (51)
Webinars (12)
Section
Business (204188)
Career Advice (2008)
Deals (35421)
Drug Delivery (95)
Drug Development (81054)
Employer Resources (172)
FDA (16189)
Job Trends (14864)
News (345231)
Policy (32547)
Tag
Academia (2554)
Accelerated approval (5)
Adcomms (20)
Allergies (86)
Alliances (49444)
ALS (95)
Alzheimer's disease (1384)
Antibody-drug conjugate (ADC) (132)
Approvals (16187)
Artificial intelligence (265)
Autoimmune disease (22)
Automation (17)
Bankruptcy (360)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (176)
Bladder cancer (79)
Brain cancer (27)
Breast cancer (292)
Cancer (2320)
Cardiovascular disease (179)
Career advice (1677)
Career pathing (30)
CAR-T (155)
Cell therapy (437)
Cervical cancer (20)
Clinical research (66093)
Collaboration (857)
Company closure (2)
Compensation (569)
Complete response letters (19)
COVID-19 (2590)
CRISPR (41)
C-suite (251)
Cystic fibrosis (102)
Data (2337)
Decentralized trials (2)
Denatured (19)
Depression (44)
Diabetes (275)
Diagnostics (6382)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (105)
Drug shortages (25)
Duchenne muscular dystrophy (97)
Earnings (87069)
Editorial (39)
Employer branding (21)
Employer resources (146)
Events (112666)
Executive appointments (743)
FDA (17570)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (773)
Gene editing (109)
Generative AI (20)
Gene therapy (314)
GLP-1 (719)
Government (4432)
Grass and pollen (4)
Guidances (162)
Healthcare (18820)
Huntington's disease (24)
IgA nephropathy (28)
Immunology and inflammation (125)
Indications (29)
Infectious disease (2735)
Inflammatory bowel disease (143)
Inflation Reduction Act (9)
Influenza (52)
Intellectual property (98)
Interviews (312)
IPO (16529)
IRA (40)
Job creations (3633)
Job search strategy (1422)
Kidney cancer (10)
Labor market (43)
Layoffs (475)
Leadership (17)
Legal (7910)
Liver cancer (76)
Lung cancer (325)
Lymphoma (157)
Machine learning (9)
Management (58)
Manufacturing (329)
MASH (77)
Medical device (13385)
Medtech (13390)
Mergers & acquisitions (19468)
Metabolic disorders (708)
Multiple sclerosis (83)
NASH (16)
Neurodegenerative disease (94)
Neuropsychiatric disorders (27)
Neuroscience (1943)
NextGen: Class of 2025 (6512)
Non-profit (4480)
Now hiring (40)
Obesity (371)
Opinion (205)
Ovarian cancer (81)
Pain (91)
Pancreatic cancer (88)
Parkinson's disease (154)
Partnered (22)
Patents (245)
Patient recruitment (116)
Peanut (46)
People (57349)
Pharmaceutical (63)
Pharmacy benefit managers (20)
Phase I (20593)
Phase II (29111)
Phase III (21677)
Pipeline (1385)
Policy (147)
Postmarket research (2563)
Preclinical (8761)
Press Release (64)
Prostate cancer (108)
Psychedelics (30)
Radiopharmaceuticals (247)
Rare diseases (385)
Real estate (5907)
Recruiting (65)
Regulatory (22328)
Reports (47)
Research institute (2321)
Resumes & cover letters (349)
Rett syndrome (6)
RNA editing (5)
RSV (42)
Schizophrenia (72)
Series A (132)
Series B (91)
Service/supplier (11)
Sickle cell disease (52)
Special edition (16)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3580)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (51)
The Weekly (30)
Vaccines (699)
Venture capitalists (42)
Weight loss (237)
Women's health (36)
Worklife (16)
Date
Today (114)
Last 7 days (961)
Last 30 days (3213)
Last 365 days (32470)
2025 (11947)
2024 (35219)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54084)
2019 (46538)
2018 (35019)
2017 (32109)
2016 (31481)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (718)
Alabama (54)
Alaska (7)
Arizona (233)
Arkansas (13)
Asia (37884)
Australia (6193)
California (6427)
Canada (2068)
China (539)
Colorado (274)
Connecticut (281)
Delaware (158)
Europe (81414)
Florida (957)
Georgia (216)
Idaho (57)
Illinois (547)
India (25)
Indiana (323)
Iowa (11)
Japan (173)
Kansas (106)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (922)
Massachusetts (4776)
Michigan (226)
Minnesota (405)
Mississippi (2)
Missouri (82)
Montana (27)
Nebraska (25)
Nevada (68)
New Hampshire (63)
New Jersey (1798)
New Mexico (28)
New York (1809)
North Carolina (992)
North Dakota (8)
Northern California (2837)
Ohio (210)
Oklahoma (14)
Oregon (34)
Pennsylvania (1429)
Puerto Rico (13)
Rhode Island (33)
South America (1097)
South Carolina (26)
South Dakota (1)
Southern California (2414)
Tennessee (106)
Texas (951)
United States (24067)
Utah (188)
Virginia (152)
Washington D.C. (64)
Washington State (566)
West Virginia (3)
Wisconsin (56)
700,053 Results for "scynexis inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update
March 13, 2025
·
10 min read
Press Releases
SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
April 9, 2025
·
5 min read
Business
SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the first quarter ended March 31, 2024.
May 8, 2024
·
9 min read
Business
SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the year ended December 31, 2023.
March 28, 2024
·
11 min read
Press Releases
SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit
October 10, 2024
·
1 min read
Press Releases
SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 7, 2024
·
10 min read
Press Releases
SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections
December 19, 2024
·
4 min read
Drug Development
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)
SCYNEXIS, Inc. announced the presentation of preclinical efficacy data on its second generation fungerp candidate SCY-247 at the ESCMID Global 2024 congress in Barcelona, Spain from April 27-30, 2024.
April 30, 2024
·
7 min read
Pharm Country
SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference
SCYNEXIS, Inc. (NASDAQ: SCYX) today announced David Angulo, M.D., President and Chief Executive Officer, will present at Guggenheim’s 6th Annual Biotechnology Conference on Wednesday, February 7 at 11:00 A.M. ET.
January 30, 2024
·
1 min read
Pharm Country
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
SCYNEXIS, Inc. (NASDAQ: SCYX) today announced the presentation of preclinical efficacy data on its second-generation fungerp candidate SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, Spain from April 27-30, 2024.
April 9, 2024
·
5 min read
1 of 70,006
Next
